• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-12

  Masitinib (AB1010, SKU A2942) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for focused KIT and PDGFRα/β studies, including cancer biology, mastocytosis research, and inflammatory cell assays. It is not a suitable choice for broad-spectrum kinase profiling or workflows requiring aqueous or ethanol solubility.

• SB525334 for TGF-beta1 Receptor Research

  2026-08-12

  SB525334 provides a selective way to interrogate ALK5-driven Smad2/3 signaling in fibrosis, renal disease, and wound-repair models. This guide connects practical cell-based workflows with the bone-transport diabetic foot ulcer study, while emphasizing controls, exposure limits, and context-dependent interpretation.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-11

  Masitinib (AB1010) provides a DMSO-compatible tool for selective KIT, PDGFRα, and PDGFRβ inhibition in cell-based and biochemical research. It is appropriate for targeted cancer, mastocytosis, and mast-cell studies, but not for aqueous or ethanol-based assays or experiments requiring broad-spectrum kinase inhibition.

• DOT1L Inhibition in Renal Fibrosis: Study Insights

  2026-08-11

  The reference study identifies DOT1L-mediated H3K79 methylation as a modifiable regulator of renal fibroblast activation and epithelial–mesenchymal transition in obstructive kidney injury. Using EPZ5676 and DOT1L siRNA, the authors connect DOT1L blockade with reduced profibrotic signaling and preservation of renoprotective factors, providing a mechanistic basis for studying epigenetic control of renal fibrosis.

• E-64: From Irreversible Chemistry to Translation

  2026-08-10

  E-64 offers a powerful way to connect cysteine protease mechanism with translational decision-making. This article examines its covalent chemistry, evidence from a salt-sensitive hypertension model, assay design considerations, and the strategic trade-offs between broad pathway interrogation and precise target attribution.

• Prmt1–Ddx17 Axis in Osteoblast Differentiation

  2026-08-09

  The reference study proposes a mechanistic link between PRMT1-dependent arginine methylation, Ddx17 protein stability, and Sh2b1 alternative splicing during osteoblast differentiation. Its findings position the PRMT1–Ddx17–Sh2b1 pathway as a candidate regulator of impaired bone formation, while the cell-based design also highlights the need to separate proliferation, viability, and lineage-specific differentiation readouts.

• EZ Cap™ mCherry mRNA: Cap 1 Reporter Guide

  2026-08-08

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is a Cap 1 red fluorescent protein mRNA for transient reporter expression, cell tracking, and localization studies. Its modified nucleotides, approximately 100-nucleotide poly(A) tail, and defined storage formulation are designed to support mRNA stability and translation enhancement while reducing RNA-mediated innate immune activation.

• ERK Links IFNγ to Melanoma Cell Death

  2026-08-07

  Champhekar et al. identify ERK as a major mediator of IFNγ-induced apoptosis in melanoma, connecting canonical IFNγ–STAT1 signaling to a stress program involving DR5 and NOXA. Complementary chemical-genetic, CRISPR, transcriptomic, imaging, and apoptosis assays show that this mechanism operates across diverse melanoma genotypes but is not universal.

• Anlotinib Hydrochloride: Precision Angiogenesis Inhibition f

  2026-08-07

  Explore how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, transforms angiogenesis research with unmatched selectivity and functional assay reliability. This article provides a unique deep dive into its pharmacological precision and evidence-based practical protocols.

• Anlotinib in IADSRCT: First Clinical Case and Mechanistic Co

  2026-08-06

  This article examines the first documented case of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in the treatment of intra-abdominal desmoplastic small round cell tumor (IADSRCT). The report details significant clinical response and mechanistic implications for targeting angiogenesis in aggressive sarcomas, with discussion of experimental design and translational potential.

• Translating Angiogenesis Blockade: Anlotinib Hydrochloride i

  2026-08-06

  Explore how Anlotinib hydrochloride, a next-generation multi-target tyrosine kinase inhibitor, is redefining translational cancer research by integrating mechanistic precision with strategic assay guidance. This thought-leadership article synthesizes current evidence, experimental design parameters, and product intelligence to empower researchers targeting angiogenesis and tumor proliferation.

• Vitamin D/VDR Pathway Enhances Endometrial Decidualization i

  2026-08-05

  This study elucidates how 1,25-dihydroxy vitamin D3, via vitamin D receptor (VDR) signaling, promotes human endometrial stromal cell decidualization by regulating estrogen synthesis and key differentiation markers. Findings provide a mechanistic foundation for exploring vitamin D's role in reproductive health and endometrial receptivity.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Technical Application

  2026-08-05

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) addresses the need for specific detection of HMGB1 protein in human, mouse, and rat samples for research purposes, supporting workflows such as Western blot, immunohistochemistry, and flow cytometry. It is not validated for diagnostic or therapeutic use and should only be used under controlled laboratory conditions within research applications.

• Pravastatin Sodium: Advanced Workflows for Cholesterol Biosy

  2026-08-04

  Pravastatin sodium empowers precision research into cholesterol metabolism, LDL reduction, and drug-transporter interplay. This guide delivers optimized protocols, troubleshooting strategies, and actionable insights for maximizing experimental reproducibility and translational value.

• Anlotinib Hydrochloride: Precision in Angiogenesis Assays

  2026-08-04

  Explore the scientific depth of Anlotinib hydrochloride as a multi-target tyrosine kinase inhibitor for angiogenesis and tumor proliferation assays. This article uniquely dissects assay design, protocol nuances, and practical research decisions for advanced cancer research.

15296 records 1/1020 page Next 12345 下5页 Last page